Commercial immunoglobulin products now contain neutralising antibodies against SARS-CoV-2 spike protein which are detectable in patient serum

Vinit Upasani, Mary O’Sullivan, Fernando Moreira, Sarita Workman, Andrew Symes, Siobhan O Burns, Susan Tadros, Laura McCoy, David M Lowe
doi: https://doi.org/10.1101/2022.09.22.22280216

Article Information

doi 
https://doi.org/10.1101/2022.09.22.22280216
History 
  • September 26, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Vinit Upasani1,
  2. Mary O’Sullivan2,
  3. Fernando Moreira2,
  4. Sarita Workman2,
  5. Andrew Symes2,
  6. Siobhan O Burns1,2,
  7. Susan Tadros2,
  8. Laura McCoy1 and
  9. David M Lowe1,2,*
  1. 1Institute of Immunity and Transplantation, University College London, London, UK
  2. 2Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK
  1. ↵*Correspondence:
    Dr David M Lowe, Institute of Immunity and Transplantation, University College London, Pears Building, Rowland Hill Street, NW3 2PP, London, UK, d.lowe{at}ucl.ac.uk
Back to top
Posted September 26, 2022.
Download PDF
Data/Code
Email
Commercial immunoglobulin products now contain neutralising antibodies against SARS-CoV-2 spike protein which are detectable in patient serum
Vinit Upasani, Mary O’Sullivan, Fernando Moreira, Sarita Workman, Andrew Symes, Siobhan O Burns, Susan Tadros, Laura McCoy, David M Lowe
medRxiv 2022.09.22.22280216; doi: https://doi.org/10.1101/2022.09.22.22280216
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area